Evidence map›Paper›PMID 34196613›Full record

ArticleActa crystallographica. Section F, Structural biology communications2021

PAIREF: paired refinement also for Phenix users.

Martin Malý, Kay Diederichs, Jan Dohnálek, Petr Kolenko

Abstract read
In one paragraph

Article in Acta crystallographica. Section F, Structural biology communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Tetracycline-modifying enzyme SmTetX from Stenotrophomonas maltophilia.Acta crystallographica. Section F, Structural biology communications · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Martin MalýFaculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, 115 19 Prague 1, Czech Republic.ORCID 0000-0002-6081-9291
Kay DiederichsUniversity of Konstanz, Box M647, 78457 Konstanz, Germany.ORCID 0000-0001-5360-0905
Jan DohnálekInstitute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Průmyslová 595, 252 50 Vestec, Czech Republic.ORCID 0000-0002-8083-7980
Petr KolenkoFaculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, 115 19 Prague 1, Czech Republic.ORCID 0000-0002-4619-9276

Funding

Akademie Věd České Republiky 86652036České Vysoké Učení Technické v Praze SGS19/189/OHK4/3T/14Grantová Agentura České Republiky 18-10687SMinisterstvo Školství, Mládeže a Tělovýchovy CZ.02.1.01/0.0/0.0/15_003/0000447Ministerstvo Školství, Mládeže a Tělovýchovy CZ.02.1.01/0.0/0.0/16_019/0000778Ministerstvo Školství, Mládeže a Tělovýchovy CZ.1.05/1.1.00/02.0109
6 · The paper itself

Abstract

In macromolecular crystallography, paired refinement is generally accepted to be the optimal approach for the determination of the high-resolution cutoff. The software tool PAIREF provides automation of the protocol and associated analysis. Support for phenix.refine as a refinement engine has recently been implemented in the program. This feature is presented here using previously published data for thermolysin. The results demonstrate the importance of the complete cross-validation procedure to obtain a thorough and unbiased insight into the quality of high-resolution data.

Indexed as

Databases, ProteinSoftwareCrystallography, X-Rayhigh-resolution limitmacromolecular crystallographypaired refinementPAIREFPhenixX-ray diffraction

Identifiers

PMID34196613
PMCPMC8248825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.